Kern Pharma is involved in the development, manufacturing, and marketing of generic medicinal products, as well as biosimilar medicines and health products aimed at improving women's health.

Kern Pharma

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Dennis Gillings

IQVIA Holdings Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Kyung Ae Lee

Thomas A Wynn

Christina Warren

Pfizer Inc.

Acobur Asesores is a consulting firm with extensive experience in public healthcare contracting in Spain and Portugal. The firm assists in all stages of the bidding process.

Metric
Company Name	Kern Pharma	IQVIA Holdings Inc.	Pfizer Inc.	Acobur Asesores
Symbol		IQV	PFE
MSH ID	COM:KERNPHARMA	COM:IQVIA	COM:PFIZER	ES:ACOBUR
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare	Commercial & Professional Services
Industry	Pharmaceuticals	Medical - Diagnostics & Research	Drug Manufacturers - General	Consulting
Country	ES	US	US	ES
Stage
Employee Count		87K	88K
Website	kernpharma.com	iqvia.com	pfizer.com	acobur.es
LinkedIn			pfizer
Founders

Metric
Market Cap	38.62B	160.65B
Enterprise Value
Monthly Web Traffic		1.84M
Web Traffic Growth		0.15
Valuation
Raised Capital		1B

Metric
Revenue	15.01B	58.50B
Revenue (LTM)
Revenue (NTM)
Gross Profit	4.13B	29.28B
EBITDA	3.21B	10.53B
Operating Income	2.08B	4.24B
Net Income	1.36B	2.12B
EPS	7.39	0.38
Diluted EPS	7.29	0.38
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.33	0.52
Operating Profit Margin	0.14	0.06
EBITDA Margin	0.21	0.18
Net Profit Margin	0.09	0.04
Return on Equity	0.23	0.02
Return on Assets	0.05	0.01
Return on Capital Employed	0.11	5.56

COM:KERNPHARMA

Kern Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	34.55	14.35
P/B Ratio	6.64	1.55
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.06	3.21
EV Multiple	10.17	17.74

Metric
Days Sales Outstanding	80.49	79.90
Days Payables Outstanding	118.21	72.06
Days Inventory Outstanding		155.46
Operating Cycle	93.44	230.19
Cash Conversion Cycle	93.44	160.85
Asset Turnover	0.58	141.27

Metric
Operating Cash Flow	2.15B	8.70B
Free Cash Flow	1.50B	4.79B
Cash Flow to Debt	0.18	0.12
Operating Cash Flow/Sales	0.16	0.16
Free Cash Flow Yield	0.03	0.05

Metric
Cash & Equivalents	1.38B	2.85B
Accounts Receivable	-388M	347M
Inventory		10.19B
Goodwill	14.57B	67.78B
Debt to Capitalization	0.69	0.45
Debt to Assets	0.53	0.30
Current Ratio	0.79	2.38
Quick Ratio	0.85	94.70

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02	0.01
R&D to Revenue		0.17
SG&A to Revenue